Pharsight

Medicure patents expiration

1. Aggrastat patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6770660 MEDICURE Method for inhibiting platelet aggregation
May, 2023

(4 months ago)

Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 May, 1998

Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in ...

Dosage: INJECTABLE;INJECTION; SOLUTION;INJECTION

How can I launch a generic of AGGRASTAT before it's drug patent expiration?
More Information on Dosage

AGGRASTAT family patents

Family Patents

2. Zypitamag patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8829186 MEDICURE Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof
Jan, 2031

(7 years from now)

Drugs and Companies using PITAVASTATIN MAGNESIUM ingredient

Market Authorisation Date: 14 July, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ZYPITAMAG family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic